Biomay Ag

Biolife Science Qld Limited

Imugene Ltd.

Bio Life Science Forschungs - Und Entwicklungsgesellschaft Mbh

Bio Life Science Forschungs- Und Entwicklungsges.m.b.h.

Ursula Wiedermann

Otto Scheiner

Heimo Breiteneder

Hubert Pehamberger

Rudolf Valenta

Dietrich Kraft

Susanne Vrtala

Erika Jensen-Jarolim

Christoph Zielinski

Marianne Van Hage-Hamsten

Hans Groenlund

Johan Roennelid

Joshua Tobias

Nicholas Ede

Alex Karlsson-Parra

Otto Schreiner

Disclosed herein is a vaccine composition for raising a humoral response to PD1, and uses thereof, for treating a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1.

Vaccine composition and uses thereof

The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. 1007216A) and wherein the at least one fusion peptide comprises two or more non-contiguous B cell epitopes of Her2/neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and/or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2/neu in a patient in need thereof.

Microparticles are disclosed which comprise a bead essentially consisting of a cross-linked carbohydrate and an antigen covalently linked thereto. The microparticle can be used for the treatment of disorders of the immune system and in diagnostic tests.

Microparticles comprising carbohydrate beads covalently linked with allergen

Growing community of inventors

Vienna, Austria

Ursula Wiedermann